Gleevec

ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix thanks to new leukemia data

ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix thanks to new leukemia data aliu Thu, 05/26/2022 – 05:35